Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy

Expert Opin Biol Ther. 2008 Jun;8(6):779-90. doi: 10.1517/14712598.8.6.779.

Abstract

Background: Kidney cancer is not a homogenous entity; it is comprised of many different tumor types, with different biologies and molecular mechanisms leading to disease and therefore different treatment approaches.

Objective: To describe the genetic basis and biochemical pathways underlying inherited forms of renal cancer, specifically in four described syndromes (von Hippel-Lindau [VHL], hereditary papillary renal cancer [HPRC], Birt-Hogg-Dubé [BHD] and hereditary leiomyomatosis renal cell carcinoma [HLRCC]), and to elucidate how the understanding of these diseases enables the possibility of disease-specific approaches to therapy.

Methods: A systematic review of the published literature on inherited and sporadic forms of renal cancer was performed.

Conclusion: Understanding of the biology and mechanisms of different forms of kidney cancer provides an opportunity for development of new treatment options.

Publication types

  • Research Support, N.I.H., Intramural
  • Review
  • Systematic Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Renal Cell / genetics
  • Carcinoma, Renal Cell / therapy
  • Drug Design
  • Fumarate Hydratase / deficiency
  • Fumarate Hydratase / genetics
  • Fumarate Hydratase / physiology
  • Genes, Tumor Suppressor*
  • Genetic Predisposition to Disease
  • Humans
  • Kidney Neoplasms / genetics*
  • Kidney Neoplasms / therapy
  • Leiomyomatosis / genetics
  • Leiomyomatosis / therapy
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / physiology
  • Neoplasms, Multiple Primary / genetics
  • Neoplasms, Multiple Primary / therapy
  • Neoplastic Syndromes, Hereditary / genetics*
  • Neoplastic Syndromes, Hereditary / therapy
  • Proto-Oncogene Proteins / antagonists & inhibitors
  • Proto-Oncogene Proteins / deficiency
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins / physiology
  • Proto-Oncogene Proteins c-met
  • Proto-Oncogenes*
  • Receptors, Growth Factor / antagonists & inhibitors
  • Receptors, Growth Factor / deficiency
  • Receptors, Growth Factor / genetics
  • Receptors, Growth Factor / physiology
  • Tumor Suppressor Proteins / deficiency
  • Tumor Suppressor Proteins / genetics
  • Tumor Suppressor Proteins / physiology
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Von Hippel-Lindau Tumor Suppressor Protein / genetics
  • Von Hippel-Lindau Tumor Suppressor Protein / physiology
  • von Hippel-Lindau Disease / genetics
  • von Hippel-Lindau Disease / therapy

Substances

  • Antineoplastic Agents
  • FLCN protein, human
  • Neoplasm Proteins
  • Proto-Oncogene Proteins
  • Receptors, Growth Factor
  • Tumor Suppressor Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Von Hippel-Lindau Tumor Suppressor Protein
  • MET protein, human
  • Proto-Oncogene Proteins c-met
  • Fumarate Hydratase
  • VHL protein, human